Expert Protein Analysis Services
Protein Characterization

Protein Characterization

Proteins are complex molecular entities derived from biological processes. They differ from each other in their size, molecular structure and physiochemical properties. These differences allow for protein analysis and characterization by separation and identification.

Protagen Protein Services (PPS) offers protein analytics as part of an integrated package of expert analytical services. With more than 20 years working in antibody characterization we have extensive experience in developing and establishing protein characterization methods to help our clients generate the data needed to gain the level of product characterization required for regulatory submission. These characterization services are also a part of our stability and product release support services, where we offer key identity, purity and potency assays.

Protein Analysis

PPS offers analytical capabilities and instrumentation to support your research through all phases of development, from IMPD/IND to achieve NDA/BLA/MAA. As an advanced analytical laboratory and mass spectrometry expert, we serve clients who require expertise in recombinant glycoprotein and complex biologics characterization services. We specialize in a broad range of analytical testing techniques to support characterization and development of both recombinant protein and peptide therapeutics. Our team of experts, complemented by our cutting-edge technology, supports our clients while upholding the highest standards of quality, technical analysis, and reporting.

In the production processs they are almost always not fully purified and homogeneous molecules, but instead show a certain degree of structural heterogeneity. This means that the characterization of a protein always has three aspects:

•    Identification of the major protein component
•    Identification of the minor components
•    Quantification of the minor components (both process- and product-related impurity characterization)

Separation is typically done via electrophoresis where proteins are differentiated by size or mass, and isoelectric focusing, where protein are separated by charge. These techniques can be done independently or in combination-referred to as 2D electrophoresis. Equipment for separation includes polyacrylamide gels, organic stains, electrophoresis boxes, isoelectric focusing immobilized strips, 2D electrophoresis equipment, protein standards as well as capillary electrophoresis systems for cGE, CZE, cIEF and icIEF. Identification is done via mass spectrometry where molecules are ionized to determine their mass to charge ratios. Mass spectrometry equipment includes protein fractionators, GC/MS, LC/MS, CE/MS and time of flight systems. Identification can also be done via amino acid sequencing by Edman degradation, crystal imaging and surface plasmon resonance. With so many options available, laboratories typically will employ multiple strategies for protein analysis and characterization.

Protein Quantification

Accurate protein quantification is necessary to understand the total protein content in a sample or in a formulated product and is essential to protein studies in a variety of research topics. A wide array of different methods have been developed to quantify complex mixtures of proteins as well as a single type of protein. How much protein is existing? It may seem an easy question, but in practice protein quantification is a difficult task. Being a sensitive measurement, large errors are easy to make and there are only a limited number of accurate methods available.

We’ve put a lot of work into developing and optimizing the methods we use. Now, we offer our own specially developed techniques that give high precision measurements and accuracy.
Furthermore, we cross-validate our methods so that you don’t have to just take our word for it. We can show that our methods do what we said they would.
So if you need to know the precise quantity of a protein in your drug development or research project, you can choose from the following services.

  • Amino Acid Analysis (AAA), to determine the amino acid composition of a protein without using an external standard.
  • Extinction Coefficient (A280), to calculate protein concentration by measuring UV absorbance at A280. This technique helps demonstrate consistency and comparability between batches.
  • Protein A HPLC (PA-HPLC) to specifically determine the concentration of an antibody.

Note that protein concentration can also be determined by ELISA assays or mass spectrometry using absolute quantification (AQUA).

Protein quantification is a key part of ICH Q6B.

  • Amino Acid Analysis (AAA)
  • Protein content by UV
  • Extinction Coefficient
  • Quantification by Protein-A HPLC
  • Isotope Dilution Mass Spectrometry

Amino Acid Analysis

Accurate quantification of peptides and proteins is essential for biotechnology, clinical chemistry, proteomics, and systems biology. During the development of a biopharmaceutical drug and other research projects, it is necessary to determine exact protein quantities. The reference method to quantify peptides and proteins is amino acid analysis (AAA). The protein content must be measured with highest accuracy and precision, because it is fundamental to determination of the dose of the drug product as well as to quantification of most of the other critical quality attributes. Naturally, the quantity of the drug substance and drug product need to be specified according to ICH Q6B.

Standard AAA, including hydrolysis, is a powerful tool for determining the precise protein content of a sample without the use of a reference standard. But AAA is an even more powerful tool when carried out with our time-resolved hydrolysis, which enables the determination of the precise amino acid composition of any peptide or protein. AAA is performed according to PharmEu.

Applications of AAA:

  • Determination of the protein content (Quantity)
  • Determination of the extinction coefficient (in combination with UV absorption)
  • Quantification of free amino acids in drug formulations, matrices and cell culture media
  • Quantification of amino acid derivatives like Norleucine (e.g. from E.coli fermentations), Hydroxyproline and Hydroxylysine


Protein Modification

One of the important areas of protein characterization is to identify those proteins that are post-translationally modified and their modification sites, and to characterize the function of the modifications. Almost all proteins, whether produced and purified as recombinant proteins or isolated from natural sources, will carry to some degree modified amino acids.

Characterizing product-related impurities is a major task. You’ll need us to analyze them with as much sensitivity and accuracy as possible. Such modifications may of course be part of the physiological function that you are developing.

But we understand that you’re keen to observe the lowest possible number of process-related modifications. The latter may occur during the sample handling process, for example in proteins that have been stored for a period of time during a stability study. They are unintentional and a source of structural heterogeneity in a protein. And that’s not what you want when you’re trying to develop a consistent, trustworthy drug substance or product.

All such changes are known as post-translational modifications and whilst some of them are desired, others are unwanted.

At Protagen, we use our mass spectrometers  to detect even the smallest and peskiest modifications, which we usually analyze using a combination of electrophoretic, HPLC and peptide mapping methods.

Normally, mass spectrometry data is qualitative rather than quantitative. However we’ll provide you with data evaluations – that is, real numbers about the degree of modification taking place in your protein – so that you get a clear picture of how your protein is doing.

You can choose from the following types of analysis:

  • Deamidation
  • Oxidation
  • Glycosylation
  • Phosphorylation
  • N- and C- terminal truncation (see N/C- Terminal Sequencing)
  • Acetylation
  • Pyroglutamate formation
  • Disulfide Linkage (mass spectrometry)
  • Free Thiols (Ellman)
  • Truncations (cGE, mass spectrometry)
  • C-terminal Lysine (IEX, cIEF + CPB)

Characterizing post-translational protein modifications is a key requirement of ICH Q6B.

  • Deamidation
  • Oxidation
  • Disulfide linkage
  • Other Modifications


The trouble with small changes - The trouble with tiny modifications in a complex molecule is the difficulty in trying to find them.
This is certainly the challenge when proteins – particularly those containing the amino acids asparagine or glutamine – have undergone deamidation. It results in the addition or removal of as little as one Dalton of molecular weight to the entire protein structure and it’s very difficult to pick up. Then there’s the issue of attempting to work out if the modification is really due to deamidation or simply due to variations in isotopic distribution, which is normal and occurs naturally in peptides. Our high-resolution mass spectrometers, coupled with an eye for detail and experienced bioinformatics team, enable us to distinguish between the two causes with reliability and high accuracy.

Furthermore, we can determine the specific sites of deamidation by undertaking peptide mapping using a high-resolution mass spectrometer and mass accuracy such as LC-ESI-MS/MS.
Analyzing deamidation is a key requirement of ICH Q6B.

Technical information

Deamidation is commonly observed as a post-translational modification of the amino acid asparagine, which turns into a mixture of isoasparate and aspartate via a succinimide intermediate. The rate of modification is influenced by factors such as the presence and interaction of surrounding amino acids, pH and temperature buffers. Deamidation of glutamine also occurs, but much less frequently.
You will be interested in finding out whether your protein has undergone deamidation because it leads to a change in isoelectic point (pI) and therefore the presence of charge heterogeneity. We can reliably observe pI changes by 1D-IEF, cIEF, icIEF or IEX-HPLC.


Protein aggregation is a common challenge in the manufacturing of biological products.

From protein expression to storage and delivery, protein aggregation is a process that can occur at any stage in the lifetime of a therapeutic protein. Albeit the specific mechanisms by which protein aggregation occurs are still not fully understood. It has been found that various aspects of the manufacturing process such as microbial contamination during cell culture or negative effects of inappropriate storage conditions can increase the risk of physical and chemical degradation due to aggregation.

As protein formation plays a highly critical role in ensuring the usability and efficacy of an injectable biopharmaceutical products, initial formation or aggregation could affect immunogenicity. Though it is important to ensure the safety, usability and stability. To monitor such potential occurance it is vital for developers to incorporate appropriate detection tools from an early stage on.

Common measurement techniques for Protein Aggregate Analytics

Various analytical methods such as Coulter Counter (CC), Micro-flow Imaging (MFI), Dynamic Imaging Particle Analysis (DIPA), and Light Obscuration (LO) can be applied to evaluate the presence of protein aggregates within the micrometer (μm) range. Multi-angle Static Light Scattering (MALS) allows for measuring the presence of protein aggregates at an early formation. Additionally, separating methods like Asymmetrical-flow Field-flow Fractionation (AF4), Analytical Ultracentrifugation (AUC), Size-exclusion Chromatography (SEC) and non-reduced capillary gel electrophoresis (cGE) are commonly applied.

Although each of these methods is proven to be efficient, none of them can directly measure protein aggregates in a solution. The required particular handling and preparation of the sample, either before or during measurement, can alter the state of the sample aggregation.

  • AUC - Analytical Ultracentrifugation
  • AF4 - Asymmetrical flow field-flow fractination
  • LO/MFI Visible + Subvisible Particles
  • cGE (non reduced)


Size Exclusion Chromatography separates protein species based on their size in a porous stationary phase. Smaller protein species are traveling through the pores of the stationary phase while bigger species cannot enter the pores and therefore elute first. This leads to a time-resolved chromatographic profile, allowing for relative quantification of protein species (aggregates, monomer, fragments) present in the sample. Equipped with an Diode Array Detector, the elution profile can be monitored at the desired wavelength. SEC has a very high resolving power and is a very robust, reproducible analysis and can- in addition to proteins- also be applied to other analytes like AAVs.

The combination with Multi Angle Laser Light Scattering (MALLS) detection and Refractive Index Detection (RID) allows for the absolute determination of the molecular weight of single species within an analyte. Furthermore, information about the radius of the species (in solution), particle content and loading of particles (e.g. AAVs with DNA) as well as quantification of full vs. empty particles can be gained. In addition, specialized analyses like determination of the Antibody-Drug-Ratio (e.g. for ADCs) as well as the PEG-Protein Ratio (for pegylated proteins) are also possible with SEC-MALLS.


Protein Primary Structure

A protein is more than the sum of its amino acids - When looking at a protein in drug development, the first step you’ll most likely want to take is an analysis of its amino acids and covalent bonds, or primary structure.

Our scientists meticulously characterize primary structure by using several separate but interlinked analysis techniques. They cross-validate the findings so that you don’t just receive the stand-alone results of each of the techniques, but an integrated report showing how the results combine to tell you more. This is something that we at Protagen Protein Services (PPS) do exceptionally well.

We are well versed in the most important techniques used to analyze primary structure today. Your project may benefit from a couple or more; we’ll work with you to design a methodology that best suits your needs.

  • Peptide Mapping
  • De-novo sequencing
  • Intact mass
  • N/C terminal sequencing (MS)
  • N-terminal sequencing (Edman)

Peptide Mapping

Not just a protein identity test - Peptide mapping is both a regulatory requirement under ICH Q6B and a powerful tool for understanding how a protein may be modified to suit your purpose.

It provides a whole suite of information to help inform the drug development process.

One of the key benefits of engaging us in your research projects is that we’ll both fulfill regulatory requirements and provide you with full data interpretation, giving you all the information we uncover.

We pioneered the mass spectrometry analysis service for the biopharmaceutical industry and have been leaders for almost 15 years, making us your peptide mapping specialists.

Our bioinformatics staff, who dedicate their time to analyzing mass spectrometry outputs, know that there are a number of ways in which peptides can be mapped in a laboratory. But each method has strengths and weaknesses depending on your situation.

We design the study so that we are using the method with the greatest strengths for your specific project. Other protein service providers don’t have a similar breadth of options when it comes to peptide mapping with mass spectrometry.

Mapping peptides was once the domain of chromatography and UV research. However, these simple methods of analysis did not allow for the identification of individual peptides without great difficulty.

Now, with our superior understanding of modern mass spectrometry, we can identify and analyze individual peptides within a protein with great certainty. And because Protagen’s scientists were at the forefront of mass spectrometry software development when it emerged almost 15 years ago, clients benefit from our finely tuned skills in this area.

Technical information

Peptide mapping is commonly undertaken to analyze the protein primary structure after cleavage of the protein into proteolytic peptides. The power of peptide mapping lies in the large number of site specific molecular features that can be detected.

When using one digestion enzyme (for example, Trypsin), peptide mapping is typically carried out for protein identification. The analysis is performed using MALDI-MS/MS or LC-ESI-MS/MS, for example during protein identification after electrophoresis, such as 1D or 2D PAGE.

When using multiple enzymes, peptide mapping is applied for the confirmation of a complete amino acid sequence, for example when confirming the amino acid sequence of a biosimilar and comparing it with the originator molecule.

Depending on the experimental setup, peptide mapping can also be used to determine the N- and C-terminus of a protein. This is sometimes crucial information for our clients, for example in the case of monoclonal antibodies, where the truncation level of the C-terminal Lysine can be monitored.

Proteins and peptides are ionized and fragmented in the mass spectrometer. The resulting MS/MS spectra is used to sequence the individual amino acids in order of their appearance in a protein or peptide.

In combination with additional sample preparation, peptide mapping can also be used to determine:

If the protein sequence is not found in a protein database, it can be deduced by de-novo sequencing.

Up to 100% sequence coverage confirms the amino acid sequence. The identification is based on LC-ESI-MS/MS data, which allows the sequencing of peptides with high confidence. Overlapping peptide sequences confirm the order of amino acids in the sequence.

Impurity Charaterization

Despite purification respectively polishing processes in protein preparation, it’s not possible to create proteins without host cell proteins. In addition to these process-related impurities there are also product-related impurities to be caused by protein modifications. 
Protein impurities may generate undesired side effects. So characterizing protein impurities is a key requirement of ICH Q6B.

We identify and quantify all the proteins in your mixture using mass spectrometry. By carrying out a bioassay, we can also see if the impurities are influencing the efficacy. Finally, we eliminate the unwanted proteins one step at a time by focusing on the differences in their characteristics. The process is tailored to your needs because every client’s requirements are different.


  • Process- and Product-Related Impurities by Charge (IEX, cIEF, CZE)
  • Process- and Product-related Impurities by Size (cGE, SEC)
  • Protease activity using customized FRET technology
  • HCP analytics (ELISA, Mass Spectrometry)
  • Endotoxin Tests

Process- and Product-Related Impurities by Charge (IEX, cIEF, CZE)

High Performance Liquid chromatography (HPLC)

Characterizing protein impurities is a key requirement of ICH Q6B since they may affect the biological activity of biopharmaceutical proteins. Process- and product-related impurities result from posttranslational modifications or degradation, generating species with e.g. different charge profiles.  

Ion Exchange (IEX) HPLC separates charge variants in protein samples and allows their relative quantification. Charged analytes in the mobile phase electrostatically interact with the countercharged stationary phase. The charge variants elute depending on their net surface charge, when a salt or pH gradient of the mobile phase is applied. Thereby, the analyte is either displaced by an increasing number of salt ions, or the analyte becomes neutral when the pH corresponds to its isoelectric point.

IEX HPLC is particularly useful for

  • relative quantification of charge variants.
  • identification of C-terminal lysine variants in monoclonal antibodies by prior carboxypeptidase B (CPB) digestion.
  • fractionation of charge variants for subsequent identification by MS (e.g. deamidation, oxidation, fragmentation) or further characterization with other techniques.
  • assessing an IEX “fingerprint” for comparison of biosimilar to originator molecule or for release testing.


Applications in Pharma-Biotech

  • Optimization and characterization of Up-Stream and Down-Stream-Processing (USP&DSP) steps in the context of protease burden
  • Characterization of protein-containing or protein-based drugs
  • Comparability of protein-containing or protein-based drugs
  • Assessment of presence of proteases in drug product causing stability issues

 Application in Diagnostics

  • Quality control of protein-based raw materials such as Serum Albumin or IgG molecules
  • Quality control of complex buffers or of final immuno assay used as diagnostic kit


Development of a fluorescence resonance energy transfer peptide library technology for detection of protease contaminants in protein-based raw materials used in diagnostic assays; Kapprell HP, Maurer A, Kramer F, Heinrich B, Buenning C, Narvaez A, Kalbacher H, Flad T (download

Higher Order Structure

Developing the formulation of a biopharmaceutical can be challenging and a solid understanding of the structure and conformation of your product is essential. Correct higher order structure (HOS) is critical to ensuring proper functionality, activity, and stability of a biopharmaceutical product. A well-developed panel of methods for HOS characterization is an essential component of a complete product characterization program.

Different formulations may alter the secondary and tertiary structure of a biopharmaceutical, which in turn can affect protein activity. PPS provides analytical methods to analyze the structure and stability of your biopharmaceutical in its formulation.

  • Circular Dichroism (CD Spectroscopy)
  • Infrared Spectroscopy (FT-IR)
  • Differential Scanning Calorimetry (DSC)
  • Dynamic light scattering (DLS)
  • Fluorescence Spectroscopy
  • H-D-Exchange Analysis (HDX mass spectrometry)

Circular Dichroism (CD Spectroscopy)

Circular dichroism (CD) is a method based on the differential absorption of left (LCP) and right circularly polarized (RCP) light by optically active chiral molecules. The difference between the absorbance of LCP and RCP light, the so-called molar ellipticity, is plotted against the wavelength and defines a circular dichroism spectrum (Figure 1). 

CD spectroscopy has a wide range of applications in many different fields, particularly for evaluating the structure of biomolecules like proteins and polypeptides: CD effects in the far UV ((below 250 nm) range, caused by the proteins amide backbone, provide information about  the secondary structure of a protein, due to characteristic CD bands with positive and/or negative ellipticities at defined wavelengths for each secondary structure element (see Figure 1). CD effects in the near UV range (~ 320-250 nm) are due to the presence of aromatic side chains or/and disulfide bridges and reflects the protein tertiary structure. Its spectral profile depends on the type and number of aromatic amino acids and their environment (e.g. degree of hydrogen bonding), therefore it differs substantially between individual proteins, and thus can be considered as a fingerprint region of a protein.

PPS is an expert in CD Spectroscopy, in particular in the determination of the higher order structure of protein based biotherapeutics, in assessing the comparability of higher order structure of Biosimilar relative to Innovator / Reference Medicinal Products, in evaluating the protein stability through temperature ramps (thermal denaturation analysis) and in finding solutions for individual customer-specific CD requirements.



Do you need to investigate glycosylation to ensure protein structural integrity during drug development? Would you like to see if any molecular alterations have taken place during fermentation, purification or storage?

Proteins that have undergone glycosylation are incredibly complex. Several glycans may be attached to numerous amino acids, and each glycan will show unique and sometimes unexpected branching.

You’ll want only the most experienced researchers looking at this in your proteins because of the intricacy involved. This is where our long history in specialised biopharmaceutical protein analysis is of benefit to you.

Although glycosylation analysis is a fairly new field of research, we have such an in-depth understanding of protein structure that we’re already unparalleled in terms of the level of detail, such as rigorous structural information, we can provide.

We apply a selection of techniques, depending on your circumstances, in order to obtain a complete overview of the glycans in your proteins. They include high resolution mass spectrometry, HPLC and electrophoretic methods.

Mass spectrometry is an important technique because of its high selectivity and sensitivity. It also provides information quickly. The mass spectrometry strategy we’ll employ will depend on the level of structural information you require. A typical strategy is shown below.


Once the analyses are complete, we package the results to tell you exact glycosylation sites and how the glycans are or are not contributing to the product you’re developing.

You can choose from the following types of analysis:

  •     N-linked glycosylation, to explore the attachment of N-linked glycans at the end of enzymes.
  •     O-linked glycosylation, to investigate the more complex addition of O-linked glycans, which occurs later in protein processing.
  •     Sialic acid content, to determine the type and quantity of sialic acid present at any stage of drug development, information which is helpful in further glycosylation analysis.
  •     Monosaccharide content, to determine the composition and quantity of N- and O-linked glycosylation.
  •     Glycosylation site, to work out exactly where glycans are attached to your proteins, because normally not all available sites will be occupied.

Characterizing glycosylation is a key requirement of ICH Q6B.

Technical information

Protein glycosylation is a post-translational modification that alters a protein’s structure or function. It is a very common and biologically relevant modification that may be directly involved in the formation of diseases. It also plays an important role in altering the pharmacokinetics by stabilizing the protein conformation, improving solubility or protecting from proteases.

The main challenge in the analysis of protein glycosylation is its structural complexity, which arises from a combination of factors such as:

  •     Multiple glycosylation sites per protein
  •     Multiple glycan structures attached to each site
  •     The complex, branched structure of glycans
  • N-linked Glycosylation
  • HILIC (Hydrophilic interaction chromatography )
  • O-linked Glycosylation
  • Sialic Acid Content
  • Monosaccharide Analysis
  • Glycosylation Site

N-linked Glycosylation

Together with our clients, we’re expanding in the biopharmaceutical field to build a portfolio of methodologies for glycan analysis. Our aim is to provide the best combination of methods to suit your particular purpose.

When compared with O-linked glycosylation, the analysis of N-linked glycosylation is fairly straightforward, as scientists have been researching it for a longer period of time. The fastest, most accurate and most economical way is through the use of our mass spectrometers.

Questions you might have about glycosylation that can be answered by looking at N-linked glycans include “Is my protein glycosylated?”, “What do the glycans look like?” and “Are they helping or hindering the development of my drug?”

For example, you may like us to determine the structure and heterogeneity of glycosylation for an entire protein or for each potential glycosylation site. To determine the structure of N-glycans we’ll use mass spectrometry (MALDI or LC-ESI) after labelling or permethylation. But to determine the antennary of glycans, or to quantify glycans, we’ll use HPAEC-PAD. Being a typical HPLC method, it has the advantage that you then can easily validate the assay for release testing. As the Normal-Phase HPLC HILIC  complements this setup by providing an additional, highly sensitive and high-resolution analysis of your samples, which can also be combined with mass spectrometry for N-glycan identification.

You might also ask us to find the sites of glycan attachment. We will do this either by peptide mapping or MALDI-ISD.

Other information about a protein’s glycosylation can be combined with what we know about its N-linked glycans. For example, we can determine the composition and amount of glycans attached to a protein by monosaccharide analysis and sialic acid analysis. The structural heterogeneity of a glycoprotein can be visualized using 2D PAGE or intact mass.

The characterization of protein glycosylation is a requirement of ICH Q6B.

Technical information

N-linked glycans are a common feature of glycoproteins such as EPO, antibodies and FSH. They have been shown to be important in many ways. They have an influence on protein folding as well as other factors, such as protein solubility, stability, immune reactions and cell-to-cell interactions.

N-glycosylation increases the structural heterogeneity of proteins when a range of structurally similar - but not identical - glycans are attached to each glycosylation site.

Glycosylation may be directly involved in the formation of diseases, but also plays an important role in altering the pharmacokinetics by stabilizing protein conformation, improving solubility or protecting from proteases.

The N-glycosylation profile of a recombinant protein can vary largely depending on the organism chosen for expression.

Glycosylation may be directly involved in the formation of diseases, but also plays an important role in altering the pharmacokinetics by stabilizing protein conformation, improving solubility or protecting from proteases.

The N-glycosylation profile of a recombinant protein can vary largely depending on the organism chosen for expression.

Binding Studies

  • Biological activity of antibodies
  • Definitions and requirements from authorities (EMA)
  • Characterization of interaction by SPR

Biological activity of antibodies

The measurement of biological activity is required for therapeutic antibodies at release of a new manufacturing batch and throughout the product life cycle. Since biological activity is determined based on individual product characteristics and mechanism of action, there is considerable decision-making involved when selecting, developing, switching, and maintaining appropriate bioassays. A key question for antibody therapeutics that acts as agonists or antagonists of a ligand-receptor interaction, is the question of cell-based versus binding assays.

The Fab domain provides the antibody with its specificity and mediates binding of the target antigen. Consequently, the Fab domain can be used therapeutically, for example, by preventing binding between target antigen and another protein.

Fc domain provides biological activity through immune effector functions such as antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) by binding to:

-Fc receptors (ADCC, ADCP)

-C1q (CDC)

The Fc domain also prolongs the half-life in the bloodstream through its interaction with FcRn

Compendial Assays

  • Apperance, Color, Clarity, Turbidity
  • pH, Osmolality, Density
  • Polysorbat quantification
  • Extractable volume
  • Content Uniformity of Dosage Units
  • pl determination (cIEF, IEF)

  Apperance, Color, Clarity, Turbidity


Your Contact for Protein Characterization

please call us +49 (0) 231 9742 6100

Ulrike Konrad

Head of Business Development
North/East Europe, Middle East, APAC


Protagen Protein Services (PPS) is a world leading CRO and recognized expert for analytical services in protein science regarding characterization, method development, validation and routine testing of antibodies, proteins, vaccines and other formates of biopharmaceuticals. Our sites are equipped with modern, state-of-the-art equipment for the analytical characterization of biopharmaceuticals regarding structure, purity, chemical modification, aggregation, particle formation, thermal stability e.g.. We offer service modules for analytcal support from research to approval regarding:

  • Developability
  • Clone Selection & Process Development
  • Extendend Characterization & Comparability
  • Stability & Release


Protagen Protein Services (PPS) is a world leading CRO and recognized expert for analytical services in protein science. More than 20 years of market experience and the comprehensive spectrum of validated analytical methods ensure the highest quality for customers in the pharmaceutical, biotech and life science industry.

PPS supports Biosimilar developers with a broad range of analytical methods and consulting in achieving and demonstrating Biosimilarity